Donopezil對阿茲海默症患者認知功能之療效

Effects of Donepezil on the Cognitive Function in Patients with Alzheimer's Disease

10.29478/TJP.200512.0003

張鈺姍(Yu-San Chang)；湯淑慧(Shu-Hui Tang)；陳明招(Ming-Chao Chen)；陳偉任(Wei-Jen Chen)

阿茲海默症 ； 認知功能 ； 愛憶欣 ； Alzheimer's disease ； cognitive function ； donepezil

台灣精神醫學

19卷4期（2005 / 12 / 01）

283 - 288

繁體中文

Objective: To assess cognitive response and change in neuropsychological features in patients with Alzheimer's disease (AD) treated with donopezil 5mg/day. Methods: Eighty patients with AD diagnosed according to DSM-IV and NINCDS-ADRDA criteria were recruited. All patients underwent evaluation of cognitive function (defined by Cognitive Ability Screening Instrument, CASI) before, and at 20- and 40- weeks after treatment. Repeated measures ANOVA was used to assess cognitive performance data. Results: There were 39 patients who completed the study, resulting in a droppedout rate of 5l%. CAST scores (p＜0.005), recent memory (p＜0.005), verbal fluency (p＜0.05) and orientation (p＜0.0l) showed significant improvement from baseline levels at week 20 but not at week 40 except for orientation which showed sustained improvement at week 40 (p＜0.05). Cognitive performance didn't show significant improvement at the endpoint of treatment except for orientation. Conclusion: Donepezil treatment resulted in significant cognitive improvement at week 20. The neuropsycholo-gical features showing improvement included recent memory, verbal fluency and orientation. Among these features, only orientation sustained significant improvement at the endpoint treatment at week 40. Data from this study may be a useful reference regarding the clinical use of donepezil.

Objective: To assess cognitive response and change in neuropsychological features in patients with Alzheimer's disease (AD) treated with donopezil 5mg/day. Methods: Eighty patients with AD diagnosed according to DSM-IV and NINCDS-ADRDA criteria were recruited. All patients underwent evaluation of cognitive function (defined by Cognitive Ability Screening Instrument, CASI) before, and at 20- and 40- weeks after treatment. Repeated measures ANOVA was used to assess cognitive performance data. Results: There were 39 patients who completed the study, resulting in a droppedout rate of 5l%. CAST scores (p＜0.005), recent memory (p＜0.005), verbal fluency (p＜0.05) and orientation (p＜0.0l) showed significant improvement from baseline levels at week 20 but not at week 40 except for orientation which showed sustained improvement at week 40 (p＜0.05). Cognitive performance didn't show significant improvement at the endpoint of treatment except for orientation. Conclusion: Donepezil treatment resulted in significant cognitive improvement at week 20. The neuropsycholo-gical features showing improvement included recent memory, verbal fluency and orientation. Among these features, only orientation sustained significant improvement at the endpoint treatment at week 40. Data from this study may be a useful reference regarding the clinical use of donepezil.

1. (1994).American Psychiatric Association: Diagnostic and statistical Manual of Mental Disorders.American Psychiatric Press, Washington DC:
2. Burns A,Rossor M,Hecker J(1999).The effects of donepezil in Alzheimer's disease-Result from a multinational trial.Dement Geriatr Cogn Disord,10,237-44.
3. Cummings JL(2000).Cholinesterase inhibitors: a new class of psychotropic compounds.Am J Psychiatry,157,4-15.
4. Doody RS,Gelmacher DS,Gordon B,Perdomo CA,Pratt RD(2001).Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease.Arch neurol,58,427-33.
5. Evans M,Ellis A,Watson D,Chowdhury T(2000).Sustained cognitive improvement following treatment of Alzheimer`s disease with donepezil.Iut J Geriatr Psychiatry,15,50-3.
6. Farlow MR,Cyrus PA(2000).Metrifonate therapy in Alzheimer's disease: A pooled analysis of four randomized, double-blind, placebo-controlled trials.Dement Geriatr Cogn Disord,11,202-11.
7. Greenberg SM,Tennis MK, Brown LB(2000).Donepezil therapy in clinical practice.Arch Neurol,57,94-9.
8. Homina A,Takeda M,Imai Y(2000).Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease.Dement Geriatr Cogn Disord,11,299-313.
9. Kim JM,Shin IS,Yoon JS(2002).Correlates of dropout, efficacy and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer`s disease.Iut Psychogeriatr,14,187-95.
10. Krall WJ,Sramek JJ,Culter NR(1999).Cholinesterase inhibitors: a therapeutic strategy for Alzheimer's disease.Ann Pharmacothcr,33,441-50.
11. Lopez-Pousa S,Vilalta-Franch J,Gaire-Olmo J(2001).Effectiveness of donepezil on several cognitive functions in patients with Alzheimer`s disease over 12 months.Neurologia,16,342-7.
12. Mackhann G,Drachman D,Folstein M,Katzman R,Price D,Stadlam EM(1984).Clinical diagnosis of Alzheimer's disease: report of the NJNCDS-ADRDA Work Group under the auspices of Department of Health and Human services task force on Alzheimer's disease.Neurology,34,939-44.
13. Rocca P,Cocuzza E,Marchiaro L,Bogetto F(2002).Donepezil in the treatment of Alzheimer`s disease long-term efficacy and safety.Prog Neuropsychophannacol Biol Psychiatry,26,369-73.
14. Rogers SL,Doody RS,Pratt RD,Ieni JR(2000).Long- term efficacy and safety of donepezil in the treatment of Alzheimer`s disease: an final analysis of a US multicentre open-label study.Eur Ncuropsychopharmacol,10,195-203.
15. Rogers SL,Friedhoff LT(1998).Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.Eur Neuropsychopharmacol,8,67-75.
16. Rosen WG,Mohs RC,Davis KL(1984).A new rating scale for Alzheimcr`s disease.Am J Psychiatr,141,1356-64.
17. RosIer M,Anand R,Cicin-Sain A(1999).Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial.BMJ,318,633-38.
18. Same K,Cullum CM,Martin-Cook K,Hynan L,Svetlike DA,Weiner MF(2002).Comparison of functional and cognitive donepezil effects in Alzheimcr`s disease.Int Psychogeriatr,14,181-5.
19. Weiner MF,Martin-Cook K,Foster BM,Same K,Fontaine CS,Svetlik DA(2000).Effects of donepezil on emotional/behavioral symptoms in Alzheimcr`s disease patients.J Clin Psychiatry,61,487-92.
20. Whitehouse PJ(1998).The cholinergic deficit in Alzheimer's disease.J din Psychiatry,59,19-22.
21. 王佳玉,花茂琴,邱銘章(2003).簡氏智能評估(MMSE）與臨床失智量表（CDR）在評估阿玆海默型失智症之比較.台彎精醫,17,23-31.
22. 李眉,林克能,周碧瑟,傅中玲,王署君,劉秀枝(1994).智能篩檢測驗和中文版初測結果.中國臨床心理學,2,69-73.